New treatments for HCV: Perspective from Asia

Clinical Liver Disease

Volumn 5, Issue 1, 2015, Pages 17-21

  Yu, Ming Lung ^a,b   Chuang, Wan Long ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DIRECTLY ACTING ANTIVIRAL AGENT; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ASIA; ASIAN; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

EID: 84923933332     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.442     Document Type: Review

References (12)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
2. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2014. doi: 10.1002/hep.27259. Epub ahead of print.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
4. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012;56:34-40.
5. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336-345.
6. Omata M, Kanda T, Yu M-L, Yokosuka O, Lim S-G, Jafri W, Tateishi R, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-435.
7. Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, et al. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. J Gastroenterol Hepatol 2013;28:1515-1520.
8. Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, et al. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. PLoS One 2013;8:e58882.
9. AASLD/IDSA/IAS-USA. HCV testing and linkage to care. In: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org/. Accessed April 24, 2014.
10. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology 2014;59:71-77.
11. Yu ML, Liu CH, Huang CF, Tseng TC, Huang JF, Dai CY, Lin ZY, et al. Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PLoS One 2012;7:e52048.
12. Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, Hou NJ, Hsieh MY, et al. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol 2010;25:758-765.